Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.48 |
| ▸ | IGF1R | P08069 | 9/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294900 | 0.97 | ULK1 (0.50) | ULK1IGF1RAURKANTRK1SRC | |
| SCHEMBL10294912 | 0.89 | IGF1R (0.47) | ULK1IGF1RAURKANTRK1SRC | |
| SCHEMBL10294902 | 0.85 | IGF1R (0.49) | ULK1IGF1RAURKANTRK1SRC | |
| SCHEMBL10294530 | 0.85 | AURKA (0.48) | IGF1RAURKANTRK1SRCGSK3B | |
| SCHEMBL10295014 | 0.85 | AURKB (0.64) | IGF1RAURKANTRK1SRCGSK3B | |
| SCHEMBL10294753 | 0.84 | AURKB (0.53) | IGF1RAURKANTRK1SRCGSK3B | |
| SCHEMBL10294954 | 0.83 | AURKB (0.53) | IGF1RAURKANTRK1SRCGSK3B | |
| SCHEMBL10294889 | 0.83 | AURKB (0.58) | AURKASRCGSK3BAURKB | |
| SCHEMBL10294694 | 0.82 | AURKB (0.37) | ULK1IGF1RAURKANTRK1SRC | |
| SCHEMBL10294907 | 0.82 | AURKB (0.37) | ULK1IGF1RAURKANTRK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2010144359-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | ULK1 2080/4885IGF1R 4230/4885AURKA 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.